Anavex Life Sciences (AVXL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access AVXL Annual Balance Sheets →
The balance sheet data below highlights changes in Anavex Life Sciences's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent118.33
Cash & Short-term Investments118.00
Other Receivables0.80
Income Taxes Receivable, Current NO1.00
Prepaid Expense And Other Assets Current0.82
Total Current Assets120.94
Total Assets120.14
Liabilities
Accounts Payable, Current AC0.80
Accrued Liabilities, Current AC4.04
Total Current Liabilities4.84
Total Long-term Debt0.00
Deferred Rent Credit DE0.00
Other liabilities, Noncurrent2.86
Deferred Income Current-
Total Liabilities7.69
Stockholders' Equity
Common Stock Value0.09
Additional Paid In Capital Common Stock498.00
Retained Earnings / Accumulated Deficit-385.64
Other Equity0.00
Common Stockholder's Equity112.45
Total Stockholder's Equity112.45
Liabilities & Stockholder's Equity120.14
4 historic quarters locked

Sign in to unlock the full Anavex Life Sciences balance sheet history.

About Anavex Life Sciences Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 28, 2026
  • Source: e7886_10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001731122-26-001167

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.